WO2020184703A1 - 大動脈瘤の治療用医薬組成物 - Google Patents
大動脈瘤の治療用医薬組成物 Download PDFInfo
- Publication number
- WO2020184703A1 WO2020184703A1 PCT/JP2020/011042 JP2020011042W WO2020184703A1 WO 2020184703 A1 WO2020184703 A1 WO 2020184703A1 JP 2020011042 W JP2020011042 W JP 2020011042W WO 2020184703 A1 WO2020184703 A1 WO 2020184703A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- aortic aneurysm
- aneurysm
- solvate
- rupture
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a pharmaceutical composition for the treatment of aortic aneurysm.
- a pharmaceutical composition for treating abdominal aortic aneurysm relates to a pharmaceutical composition for treating abdominal aortic aneurysm.
- An aortic aneurysm is defined as "a state in which a part of the wall of the aorta is enlarged or protrudes (diameter) globally or locally".
- part of the aortic wall dilates locally to form an aneurysm, or the diameter expands beyond 1.5 times the normal diameter (45 mm in the chest, 30 mm in the abdomen) (spindle or sac).
- it is called an "Aneurysm”.
- the annual incidence in Japan is reported to be about 3 per 100,000 population, but according to the statistics of the Japanese Society of Thoracic Surgery, the number of aortic aneurysm surgery is increasing year by year.
- Aortic aneurysms are classified according to the morphology of the aneurysm wall, the location and cause of the aneurysm, the shape of the aneurysm, and the like.
- the morphology of the aneurysm wall is classified into genuine, pseudo, and dissecting aortic aneurysms.
- the site of the aneurysm is classified into chest, thoracoabdominal, and abdominal aortic aneurysm.
- Aortic aneurysms are classified according to their cause into atherosclerotic, traumatic, inflammatory, infectious, and congenital.
- Aortic aneurysms are classified into spindle-shaped and sac-shaped based on the shape of the aneurysm.
- Abdominal aortic aneurysm (hereinafter also referred to as "AAA”) is a disease in which the aortic wall becomes fragile and expands to 1.5 times or more the normal diameter (AAA maximum minor axis over 30 mm), leading to rupture.
- the mortality rate is said to be as high as 50-90%.
- the rupture rate (% / year) of AAA is almost 0% / year when the maximum minor axis of AAA is about 30 mm, but it increases as the diameter increases, and when it exceeds 70 mm, it reaches 20-40% / year. It is said.
- AAA Drug treatment for AAA, which may rupture, has not been established, and surgical operation to prevent rupture of the aneurysm by aortic aneurysm resection (artificial blood vessel replacement) or stent graft insertion is the only treatment method. It is said that the maximum minor axis of AAA is more than 50 mm or the enlargement of 5 mm or more is recognized within half a year (references http://www.j-circ.or.jp/guideline/pdf/). JCS2011_takamoto_d.pdf).
- AAA is common in the elderly and cannot be treated in patients who cannot select aortic aneurysm resection requiring laparotomy due to poor general condition or in patients to whom stent graft cannot be applied due to morphological restrictions of the aortic aneurysm. Therefore, there is a strong demand for the development of a therapeutic agent for aortic aneurysm by preventing or suppressing the expansion and rupture of the aneurysm.
- the above facts may suggest the limits of basic research itself using these animal models. That is, in these animal models, among the intima, media, and adventitia constituting the blood vessel wall, the intima atherosclerosis and the media are externally inflamed to form an aneurysm.
- the aortic aneurysm thus induced forms only part of the pathology of human AAA. That is, it does not necessarily reflect the pathophysiology of human aortic aneurysm.
- the aneurysm does not rupture (elastase-induced or CaCl 2- induced model), the maximum minor axis does not expand persistently (AngII-induced, elastase-induced, or CaCl 2- induced model), and the wall of the aortic aneurysm. mural thrombus does not adhere to the inside (Ang II-induced, or CaCl 2 induced model) such as, often differs from the human AAA is a problem (non-Patent Document 1).
- the AngII-induced model is human AAA. It does not directly imitate. Also, unlike human AAA, in which a part of the wall of the aorta is enlarged (or protruding), the aortic wall is exfoliated into two layers and becomes two cavities along the arterial run. Therefore, pathological differences are also observed. Therefore, the AngII-induced model is not suitable as an experimental model for evaluating AAA rupture.
- Non-Patent Document 2 since there are cases in which rupture could not be suppressed even if the induction of aneurysm enlargement was suppressed in the model animal (Non-Patent Document 2), as far as the existing model is referred to, AAA by suppressing AAA expansion There is no possibility that the rupture of the animal can be suppressed.
- Non-Patent Document 3 A new animal model has been developed that is closer to the human AAA histopathological image than the conventional model by inducing circulatory insufficiency and hypoxia in the wall tissue.
- Non-Patent Document 4 a new relationship between AAA rupture and adipocyte formation in the wall was shown (Non-Patent Document 4).
- the inventors will evaluate the effect of the drug more appropriately than the conventional model by using this model created in rats (hereinafter, may be referred to as "aortic wall hypoxia-induced rat AAA model"). It was thought that it was possible.
- Compound 1 (-)-6- [3- [3-Cyclopropyl-3-[(1R, 2R) -2-hydroxycyclohexyl] ureido] propoxy] -2 (1H) -quinolinone (hereinafter referred to as "Compound 1”) ) Has anti-propyl activity, anti-thrombotic activity and PDE3 inhibitory activity, and is applicable to cerebral porridge sclerosis, cerebral infarction, transient cerebral ischemic attack, convalescent ischemic neuropathy.
- Brain diseases such as brain diseases, myocardial infarction, heart diseases such as angina, Buerger's disease, arteriosclerosis obliterans, chronic arterial occlusion such as intermittent lameness, diabetic neuropathy, diabetic skin ulcer, diabetic nephropathy, etc.
- Non-Patent Document 5 and Patent Document 1 After diabetic complications, percutaneous coronary angioplasty (PTCA), directional coronary artery disease resection (DCA), prevention of re-stenosis after intervention treatment of stents, and transplantation of artificial organs such as artificial blood vessels and kidneys It is known to prevent reocclusion of the disease, and to prevent ischemic diseases such as thrombosis during extracorporeal circulation such as artificial renal dialysis and prevention of embolization after surgery (Non-Patent Document 5 and Patent Document 1). However, it is not known that Compound 1 is effective for the treatment of aortic aneurysm, for example, treatment based on suppression of rupture or expansion of abdominal aortic aneurysm.
- statins known as HMG-CoA reductase inhibitors
- HMG-CoA reductase inhibitors are widely used worldwide for the treatment of dyslipidemia. This class of drugs is particularly effective in lowering LDL-C levels and is believed to reduce the prevalence of cardiovascular disease.
- HMG-CoA reductase inhibitors there are several reports expecting the anti-inflammatory effect of statins (Non-Patent Documents 6 to 9), but it has been pointed out that consistent results have not been obtained regarding their effectiveness (non-patent documents 6-9). Patent Document 10).
- no effect on AAA when compound 1 and statin are used in combination is known.
- An object of the present invention is to provide a therapeutic composition for aortic aneurysm, particularly a therapeutic composition for suppressing rupture or expansion of an abdominal aortic aneurysm.
- the present inventors suppressed the rupture of the abdominal aortic aneurysm in the aortic wall hypoxia-induced rat AAA model by using compound 1 and statin in combination, and further expanded the aneurysm. We have found that it suppresses and completed the present invention.
- the present invention relates to (-)-6- [3- [3-cyclopropyl-3-[(1R, 2R) -2-hydroxycyclohexyl] ureido] propoxy] -2 (1H) -quinolinone (Compound 1).
- a pharmaceutical composition for treating aortic aneurysm which comprises a salt thereof, a solvate thereof, and a statin.
- the present invention relates to a pharmaceutical composition for treating abdominal aortic aneurysm, which comprises a combination of Compound 1 or a salt thereof, a solvate thereof, and a statin.
- the treatment of abdominal aortic aneurysm of the present invention is suppression of rupture and / or expansion of aortic aneurysm
- the present invention is a combination of compound 1 or a salt thereof, or a mixture thereof, and a statin. It relates to an agent for suppressing rupture and / or spreading of an abdominal aortic aneurysm.
- the suppression of rupture of an aortic aneurysm can be said to prevent the rupture of an aortic aneurysm.
- the rupture inhibitor for (abdominal) aortic aneurysm which is one aspect of the present invention, can also be said to be a rupture preventive agent for (abdominal) aortic aneurysm.
- the present invention also relates to a therapeutic pharmaceutical composition for aortic aneurysm patients after stent graft interpolation, as one preferred embodiment.
- the pharmaceutical composition treats an aortic aneurysm by suppressing rupture, suppressing enlargement, and / or shrinking.
- the present invention relates to (-)-6- [3- [3-cyclopropyl-3-[(1R, 2R) -2-hydroxycyclohexyl] ureido] propoxy] -2 (1H) -quinolinone or a salt thereof.
- the present invention relates to a rupture inhibitor of abdominal aortic aneurysm after stent graft interpolation, which comprises a solvate thereof and a combination of statins.
- the present invention relates to a therapeutic pharmaceutical composition for aortic aneurysm patients prior to stent graft interpolation or aortic aneurysm resection (artificial blood vessel replacement).
- the therapeutic pharmaceutical composition of the present invention Prior to stent-graft interpolation or aortic aneurysm resection (artificial blood vessel replacement), the therapeutic pharmaceutical composition of the present invention is used for the treatment of aortic aneurysm (rupture suppression, enlargement suppression, and / or reduction). Be done.
- the present invention relates to (-)-6- [3- [3-cyclopropyl-3-[(1R, 2R) -2-hydroxycyclohexyl] ureido] propoxy] -2 (1H) -quinolinone or a salt thereof.
- the present invention relates to an agent for suppressing abdominal aortic aneurysm rupture before stent graft insertion or aortic aneurysm resection (artificial blood vessel replacement), which comprises a combination of solvates thereof and statins.
- the present invention relates to (-)-6- [3- [3-cyclopropyl-3-[(1R, 2R) -2-hydroxycyclohexyl] ureido] propoxy] -2 (1H) -quinolinone or a salt thereof.
- the present invention relates to a therapeutic use for aortic aneurysm in combination with their solvates and statins.
- the present invention relates to (-)-6- [3- [3-cyclopropyl-3-[(1R, 2R) -2-hydroxycyclohexyl] ureido] propoxy] -2 (1H) -quinolinone or a salt thereof, or a salt thereof.
- a solvate of the above, and a composition containing a statin are provided.
- One aspect of the composition is a pharmaceutical composition.
- One aspect of the pharmaceutical composition is a pharmaceutical composition for the treatment of aortic aneurysm. More specifically, the present invention relates to the following [1] to [49]. [1] (-)-6- [3- [3-Cyclopropyl-3-[(1R, 2R) -2-hydroxycyclohexyl] ureido] propoxy] -2 (1H) -quinolinone or a salt thereof, or a salt thereof.
- a pharmaceutical composition for the treatment of aortic aneurysm which comprises a combination of a solvate and a statin.
- the therapeutic pharmaceutical composition according to the above [1], wherein the treatment of an aortic aneurysm comprises at least one treatment selected from the group consisting of suppression of rupture of the aneurysm, suppression of expansion of the aneurysm, and reduction of the aneurysm.
- statin is a statin selected from the group consisting of pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, and rosuvastatin. ..
- statin is a statin selected from the group consisting of pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, and rosuvastatin. ..
- statin is pitavastatin or a salt thereof or a solvate thereof.
- statin is pitavastatin calcium or pitavastatin calcium hydrate.
- statin is a statin selected from the group consisting of pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, and rosuvastatin.
- statin is pitavastatin or a salt thereof or a solvate thereof.
- statin is pitavastatin calcium or pitavastatin calcium hydrate.
- statin is a statin selected from the group consisting of pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, and rosuvastatin.
- statin is pitavastatin or a salt thereof or a solvate thereof.
- statin is pitavastatin calcium or pitavastatin calcium hydrate.
- statin is a statin selected from the group consisting of pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, and rosuvastatin.
- statin is a statin selected from the group consisting of pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, and rosuvastatin.
- pravastatin simvastatin
- fluvastatin fluvastatin
- atorvastatin atorvastatin
- pitavastatin and rosuvastatin.
- rosuvastatin -[3- [3-Cyclopropyl-3-[(1R, 2R) -2-hydroxycyclohexyl] ureido] propoxy] -2 (1H) -quinolinone or a salt thereof, or a mixture thereof, and a combination of statins. ..
- statin is pitavastatin or a salt thereof or a solvate thereof.
- statin is pitavastatin or a salt thereof or a solvate thereof.
- statin is pitavastatin calcium or pitavastatin calcium hydrate.
- the present invention also relates to the inventions described as the following [A] to [G].
- a therapeutic agent for aortic aneurysm containing a solvate and statin as active ingredients.
- [D] The rupture inhibitor according to [C] above, wherein the aortic aneurysm is an abdominal aortic aneurysm.
- [E] The rupture inhibitor according to the above [C] or [D], wherein the rupture inhibitor is rupture inhibitory after stent graft interpolation.
- [F] (-)-6- [3- [3-Cyclopropyl-3-[(1R, 2R) -2-hydroxycyclohexyl] ureido] propoxy] -2 (1H) -quinolinone or a salt thereof, or a salt thereof.
- [G] The expansion inhibitor according to [F] above, wherein the aortic aneurysm is an abdominal aortic aneurysm.
- FIG. 1 shows a general diet in an aortic wall hypoxia-induced rat AAA model, or a diet in which compound 1 alone or compound 1 and pitavastatin calcium were mixed with a general diet one week before the AAA model creation operation (7 days before surgery). It is a figure which shows the secular change of the aneurysm diameter (AAA maximum minor axis) at the time of administration from.
- the vertical axis shows the diameter of the aneurysm
- the horizontal axis shows the number of days after the AAA-induced treatment (POD means the number of days after the operation).
- the box plot shows the minimum value, the first quartile, the median value, the third quartile, and the maximum value (mm) of the aneurysm diameter of each group.
- FIG. 2 shows a general feed for an aortic wall hypoxia-induced rat AAA model, or a feed obtained by mixing compound 1 and pitavastatin calcium with a general feed one week before the AAA model creation operation (7 days before surgery).
- the vertical axis is cumulative survival (survival at the time of induction treatment in the aortic wall hypoxia-induced rat AAA model is 1.0), and the horizontal axis is the number of postoperative days (the number of days after treatment with the induction treatment date as 0).
- the deaths of unknown cause observed during the observation and the sacrificial deaths associated with the end of the observation on the 28th were discontinued (x) because they do not correspond to death due to rupture or survival, and from the subsequent total of survival rate and rupture rate. Excluded.
- the number of specimens shows the survivors at the start of each time point. The number of samples is different from that in FIG. 1 because some samples died before the measurement of the aneurysm diameter at each time point.
- Compound 1 in the present invention is known and can be produced by the method described in Patent Document 1 (WO97 / 12869) or a method similar thereto. Further, in the present invention, a salt of compound 1 or a solvate can also be used. The salt and solvate of Compound 1 can be produced by a conventional method.
- Examples of the salt of compound 1 of the present invention include an addition salt with a base, and there is no particular limitation as long as it is pharmaceutically acceptable.
- Examples of such salts include base addition salts with alkali metals such as potassium and sodium, and alkaline earth metals such as magnesium and calcium.
- solvate of the compound 1 of the present invention examples include a hydrate, a solvate of alcohol (for example, a solvate of ethanol) and the like.
- the dose of compound 1 or a salt thereof, or a solvate thereof is not particularly limited and varies depending on the weight, age, sex, symptoms, etc. of the patient, and can be appropriately set by those skilled in the art, but is usually for adults. In this case, it is preferable to administer 0.01 to 1000 mg of compound 1 daily, preferably 5 to 400 mg, particularly preferably 25 to 200 mg in one or more divided doses.
- statin is an HMG-CoA reductase inhibitor, and examples thereof include pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin, salts thereof, or solvates thereof.
- Preferred statins include pitavastatin or salts thereof or solvates thereof.
- pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin or salts thereof or solvates thereof are available as commercial products.
- pravastatin or a salt thereof or a solvent product thereof includes not only pravastatin itself but also pharmaceutically acceptable salts of pravastatin (alkali metal salts such as sodium salt and potassium salt; calcium salt, magnesium salt and the like). Alkaline earth metal salt; organic amine salt such as phenethylamine salt; ammonium salt, etc.), and a solvent mixture of pravastatin and its pharmaceutically acceptable salt with water, alcohol, etc. Two or more types can be used in combination.
- pravastatin sodium (chemical name: Monosodium (3R, 5R) -3,5-dihydroxy-7- ⁇ (1S, 2S, 6S, 8S, 8aR) -6-hydroxy -2-methyl-8 [-(2S) -2-methylbutanoyloxy] -1,2,6,7,8,8a-hexahydronaphthalen-1-yl ⁇ heptanoate) is preferable.
- Pravastatin or a salt thereof or a solvate thereof is a known compound, and can be produced, for example, by the method described in JP-A-57-2240, US Pat. No. 4,346,227, and the like.
- the dose of pravastatin or a salt thereof or a solvate thereof is not particularly limited and can be appropriately examined and determined according to the sex, age, symptom, etc. of the user.
- pravastatin per day It is preferable to take 1 to 160 mg in terms of sodium, more preferably 2 to 120 mg, and particularly preferably 5 to 80 mg in one or more divided doses.
- simvasstatin includes not only simvasstatin itself but also pharmaceutically acceptable salts of simbustatin (alkali metal salts such as sodium salt and potassium salt; calcium salt, magnesium salt and the like). Alkaline earth metal salt; organic amine salt such as phenethylamine salt; ammonium salt, etc.), and also a solvent mixture of simvasstatin and its pharmaceutically acceptable salt with water, alcohol, etc., one or two of these. Can be used in combination with more than seeds.
- simvastatin or a salt thereof or a solvate thereof As simvastatin or a salt thereof or a solvate thereof, simvastatin (chemical name: (1S, 3R, 7S, 8S, 8aR) -8- [2-[(2R, 4R) -4-hydroxy-6-oxotetrahydro- 2H-pyran-2-yl] ethyl] -3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate) is preferred. Simvastatin or a salt thereof or a solvate thereof is a known compound, and can be produced, for example, by the method described in US Pat. No. 4,444,784.
- the dose of simvastatin or a salt thereof or a solvate thereof is not particularly limited and can be appropriately examined and determined according to the sex, age, symptom, etc. of the user.
- simvastatin per day It is preferable to take 1 to 160 mg, more preferably 2 to 120 mg, and particularly preferably 5 to 80 mg in 1 or 2 or more divided doses in terms of free form.
- fluvastatin or a salt thereof or a solvent product thereof includes fluvastatin itself and pharmaceutically acceptable salts of fluvastatin (alkali metal salts such as sodium salt and potassium salt; calcium salt, Alkaline earth metal salts such as magnesium salts; organic amine salts such as phenethylamine salts; ammonium salts, etc.), as well as fluvastatin and its pharmaceutically acceptable salts and solvents such as water and alcohol are also included.
- fluvastatin alkali metal salts such as sodium salt and potassium salt; calcium salt, Alkaline earth metal salts such as magnesium salts; organic amine salts such as phenethylamine salts; ammonium salts, etc.
- fluvastatin sodium (chemical name: ( ⁇ )-(3RS, 5SR, 6E) -sodium-7- [3- (4-fluorophenyl) -1- (1) -methylethyl) -1H-indol-2-yl] -3,5-dihydroxy-6-heptenoate) is preferred.
- Fluvastatin or a salt thereof or a solvate thereof is a known compound, and can be produced, for example, by the method described in Japanese Patent Application Laid-Open No. 60-500015, US Pat. No. 5,354,772 and the like.
- the dose of fluvastatin or a salt thereof or a solvate thereof is not particularly limited and can be appropriately examined and determined according to the sex, age, symptom, etc. of the user, and can be determined, for example, per day. It is preferable to take 1 to 160 mg of fluvastatin in terms of free form, more preferably 5 to 120 mg, and particularly preferably 10 to 80 mg in one or two or more divided doses.
- atorvastatin or a salt thereof or a solvent product thereof includes not only atorvastatin itself but also pharmaceutically acceptable salts of atorvastatin (alkali metal salts such as sodium salt and potassium salt; calcium salt, magnesium salt and the like). Alkaline earth metal salts; organic amine salts such as phenethylamine salts; ammonium salts, etc.), as well as atorvastatin and its pharmaceutically acceptable salts, and a solvent mixture of water, alcohol, etc., one of these or Two or more types can be used in combination.
- atorvastatin calcium hydrate (chemical name: (-)-Monocalcium bis ⁇ (3R, 5R) -7- [2- (4-fluorophenyl-5-isopropyl-3) -phenyl-4-phenylcarbamoyl-1H-pyrrol-1-yl) -3,5-dihydroxyheptanoate] trihydrate ⁇ ) is preferable.
- Atorvastatin or a salt thereof or a solvate thereof is a known compound, and can be produced, for example, by the method described in JP-A-3-58967, US Pat. No. 5,273,995 and the like.
- the dose of atorvastatin or a salt thereof or a solvate thereof is not particularly limited and can be appropriately examined and determined according to the sex, age, symptom, etc. of the user.
- atorvastatin per day In terms of free form, it is preferable to take 1 to 160 mg, more preferably 2 to 120 mg, and particularly preferably 5 to 80 mg in one or more divided doses.
- pitabastatin or a salt thereof or a solvent product thereof includes not only pitabastatin itself but also pharmaceutically acceptable salts of pitabastatin (alkali metal salts such as sodium salt and potassium salt; calcium salt, magnesium salt and the like). Alkaline earth metal salts; organic amine salts such as phenethylamine salts; ammonium salts, etc.), as well as pitabastatin and its pharmaceutically acceptable salts, and a solvent mixture of water, alcohol, etc. Two or more types can be used in combination.
- pitavastatin or a salt thereof or a solvate thereof a calcium salt of pitavastatin or a hydrate thereof is preferable, and pitavastatin calcium (chemical name: (+)-monocalcium bis ⁇ (3R, 5S, 6E) -7- [2 -cyclopropyl-4- (4-fluorophenyl) -3-quinolyl] -3,5-dihydroxy-6-heptenoate ⁇ ) or its hydrate (particularly pentahydrate) is particularly preferred.
- Pitavastatin or a salt thereof or a solvate thereof is a known compound, and can be produced, for example, by the method described in JP-A No. 1-279866, US Pat. No. 5,856,336 and the like.
- the dose of pitavastatin or a salt thereof or a solvate thereof is not particularly limited and can be appropriately examined and determined according to the sex, age, symptom, etc. of the user. For example, pitavastatin per day. It is preferable to take 0.1 to 16 mg in terms of calcium, more preferably 0.5 to 8 mg, and particularly preferably 1 to 4 mg in one or more divided doses.
- rosvasstatin or a salt thereof or a solvent product thereof includes not only rosvasstatin itself but also pharmaceutically acceptable salts of losbustatin (alkali metal salts such as sodium salt and potassium salt; calcium salt, magnesium salt and the like). Alkaline earth metal salt; organic amine salt such as phenethylamine salt; ammonium salt, etc.), and also a solvent mixture of rosbatatin and its pharmaceutically acceptable salt with water, alcohol, etc. Two or more types can be used in combination.
- Rosuvastatin or a salt thereof or a solvate thereof rosuvastatin calcium (chemical name: Monocalcium bis ((3R, 5S, 6E) -7- ⁇ 4- (4-fluorophenyl) -6-isopropyl-2- [methanesulfonyl ( methyl) amino] pyrimidin-5-yl ⁇ -3,5-dihydroxyhept-6-enoate)) is preferred.
- Rosuvastatin or a salt thereof or a solvate thereof is a known compound, and can be produced, for example, by the method described in JP-A-5-178841 and US Pat. No. 5,260,440.
- the dose of rosuvastatin or a salt thereof or a solvate thereof is not particularly limited and can be appropriately examined and determined according to the sex, age, symptom, etc. of the user.
- rosuvastatin per day It is preferable to take 0.5 to 80 mg, more preferably 1 to 60 mg, and particularly preferably 2.5 to 40 mg in 1 or 2 or more divided doses in terms of free form.
- pitavastatin or a salt thereof or a solvate thereof is particularly preferable from the viewpoint of obtaining an excellent therapeutic effect on aortic aneurysm when combined with compound 1 or a salt thereof or a solvate thereof.
- compound 1 or a salt thereof or a solvate thereof can be used in combination with an excellent effect of suppressing the expansion of the aneurysm diameter. Is recognized.
- the rupture inhibitor of the abdominal aortic aneurysm of the present invention suppresses the rupture of AAA and, by extension, prevents death due to the rupture of AAA. It can also be applied to suppress rupture of aortic aneurysms including thoracic abdominal aortic aneurysm and thoracic aortic aneurysm. It is useful as an aortic aneurysm rupture inhibitor before aortic aneurysm resection (artificial blood vessel replacement), before stent graft interpolation, or after interpolation.
- the therapeutic pharmaceutical composition for aortic aneurysm of the present invention is preferably used as a rupture inhibitor of AAA, both before and after stent-graft interpolation.
- the action of suppressing the spread of the therapeutic pharmaceutical composition for abdominal aortic aneurysm of the present invention is to suppress the spread of AAA and thus prevent death due to rupture from the spread of AAA. It can also be applied to suppress the expansion of aortic aneurysms including thoracic abdominal aortic aneurysms and thoracic aortic aneurysms. It is useful as an aortic aneurysm enlargement inhibitor before aortic aneurysm resection (artificial blood vessel replacement), before stent graft interpolation, or after interpolation.
- the pharmaceutical composition for treating aortic aneurysm of the present invention is preferably used as an agent for suppressing the spread of AAA, both before and after interpolation of the stent graft.
- the combination ratio of compound 1 or a salt thereof, or a solvate thereof and a statin is not particularly limited, and can be appropriately examined and determined according to the sex, age, symptoms, etc. of the user, but is excellent. From the viewpoint of obtaining a therapeutic effect on aortic aneurysm, it is preferable to combine 0.0001 to 16000 parts by mass of statin in terms of free form with respect to 1 part by mass of free form of Compound 1, and 0.00125 to 24 parts by mass in combination. Is more preferable, and it is particularly preferable to combine 0.005 to 3.2 parts by mass.
- pitavastatin or a salt thereof or a solvate thereof is used as the statin, from the viewpoint of obtaining an excellent therapeutic effect on aortic aneurysm, pitavastatin or a salt thereof or a solvate thereof is based on 1 part by mass of the free form of compound 1. It is preferable to combine 0.0001 to 1600 parts by mass of the solvate in terms of free form, more preferably 0.00125 to 1.6 parts by mass, and 0.005 to 0.16 parts by mass. Especially preferable.
- a therapeutic agent for aortic aneurysm which is a combination of compound 1 or a salt thereof, or a mixture thereof and a statin, is a separate preparation of the component compound 1 or a salt thereof, or a solvent thereof and a statin.
- kit formulation containing a combination of a formulation containing Compound 1 or a salt thereof, or a mixture thereof and a formulation containing a statin
- It may be administered as a pharmaceutical preparation (combination drug) containing both components, but from the viewpoint of convenience of administration, it may be administered as a combination drug containing both components. It is preferable to do so.
- a statin-containing therapeutic agent for aortic aneurysm which is administered in combination with Compound 1 or a salt thereof, or a solvate thereof, is used in combination with Compound 1 or a salt thereof, or a solvate thereof.
- a statin-containing drug may be administered simultaneously with or at intervals of a statin-containing drug containing compound 1 or a salt thereof, or a solvate thereof.
- Specific embodiments of the drug include, for example, a drug for treating an aortic aneurysm, and the following (A) and (B): (A) A drug for treating an aortic aneurysm containing a statin; (B) Instructions instructing that the drug be administered in combination with Compound 1 or a salt thereof, or a solvate thereof; Examples include pharmaceuticals containing.
- Specific examples of the instruction sheet include a so-called Noh book (package insert) and a label that describe explanatory items regarding the indication, usage, dosage, and the like.
- compound 1 or a salt thereof administered in combination with statin, or a solvate thereof for aortic aneurysm therapeutic agent is intended to be used in combination with statin, for example, compound 1 or It is advisable to administer the salt, or a solvate thereof, at the same time as or at intervals with the statin-containing drug.
- the drug include, for example, a drug for treating an aortic aneurysm, and the following (A) and (B): (A) A drug for treating aortic aneurysm containing compound 1 or a salt thereof, or a solvate thereof; (B) Instructions instructing the drug to be administered in combination with a statin; Examples include pharmaceuticals containing.
- Specific examples of the instruction sheet include a so-called Noh book (package insert) and a label that describe explanatory items regarding the indication, usage, dosage, and the like.
- the specific shape (dosage form) of the drug is not particularly limited, and may be any shape of solid, semi-solid, or liquid preparation, depending on the purpose of use and the like. You can choose.
- Examples of the dosage form of the drug include the dosage forms described in the 17th revised Japanese Pharmacopoeia General Regulations for Formulations. More specifically, the dosage form for oral administration includes tablets (for example, ordinary tablets, orally disintegrating tablets, chewable tablets, effervescent tablets, dispersion tablets, dissolving tablets, etc.), capsules, and granules.
- solid preparations such as powders; semi-solid preparations such as oral jelly preparations; oral liquid preparations (including, for example, elixirs, suspending agents, emulsions, limonade agents, etc.) and the like.
- oral liquid preparations including, for example, elixirs, suspending agents, emulsions, limonade agents, etc.
- Dosage forms for parenteral administration include injections, inhalants, eye drops, ear drops, nasal drops, suppositories, external solids, external solutions, sprays, ointments, creams, and gels. , Patches and the like.
- a solid preparation for oral administration is preferable from the viewpoint of ease of administration, and tablets, capsules, granules or powders are particularly preferable.
- the drug can be manufactured by a known method described in, for example, the 17th revised Japanese Pharmacopoeia General Formulation Regulations, etc., depending on the dosage form.
- a pharmaceutically acceptable carrier may be added to the drug.
- additives include excipients, binders, bulking agents, disintegrants, surfactants, lubricants, dispersants, buffers, preservatives, flavoring agents, fragrances, coating agents, diluents and the like. However, it is not limited to these.
- Example 1 Effect on aortic wall hypoxia-induced rat AAA model
- Rat AAA model induced by surgery to separate the aortic wall from surrounding tissue, insert a catheter, and then ligate the abdominal aorta with a thread (Non-Patent Document) The actions of compound 1 and pitabastatin in 3) were examined.
- Compound 1 was produced according to the method described in Patent Document 1, and 0.15% was mixed with a general feed (FR2, manufactured by Funabashi Farm) and used.
- FR2 manufactured by Funabashi Farm
- pitavastatin 0.003% of pitavastatin calcium was mixed with a general feed (FR2, manufactured by Funabashi Farm) and used.
- Test animal and breeding environment Sprague-Dawley male rats (300-350 g: Japan SLC) were used in the experiment. Room temperature: The animals were bred at 25 ° C ⁇ 1 ° C and fed freely with food and water.
- a rat AAA model was prepared according to the method described in Non-Patent Document 3. That is, a rat AAA model was created by separating the rat aorta wall from the surrounding tissue, inserting a polyurethane catheter, then ligating the abdominal aorta with a plastic catheter with a monofilament thread and inducing AAA.
- compound 1 group 0.15% mixed feed administration group of compound 1
- compound 1 group 0.15%
- combination group 0.15% of compound 1 and 0.003% of pitavastatin calcium
- control group 0.15%
- the general feed or each mixed feed was freely fed from 1 week before the AAA modeling operation (7 days before the operation) to the end of the experiment.
- Results The measurement results of the aneurysm diameter are shown in FIG. Compared with the control group and the compound 1 group, the expansion of the aneurysm diameter was suppressed in the combination group. In particular, the aneurysm diameter was significantly enlarged in the control group on the 14th day after the operation, on the control group and the compound 1 group on the 21st day, in the control group on the 28th day, and in the combination group. It was suppressed (both p ⁇ 0.05).
- the results of non-ruptured survival are shown in FIG. In the follow-up from the day of surgery to 28 days after surgery, the mortality rate due to rupture was lower in the compound 1 group and the combination group than in the control group, that is, the survival rate tended to improve.
- Compound 1 of the present invention is effective in suppressing rupture and / or expansion of aortic aneurysm, and has industrial applicability as enabling medical treatment for aortic aneurysm. There is.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
瘤壁の形態としては、真正、仮性、及び解離性の大動脈瘤に分類される。
瘤の存在部位としては、胸部、胸腹部、及び腹部大動脈瘤に分類される。
大動脈瘤は、その原因から動脈硬化性、外傷性、炎症性、感染性、及び先天性のものに分類される。
また、瘤の形から、大動脈瘤は紡錘状及び嚢状に分類される。
スタチンのAAAに対する効果に関しては、スタチンの抗炎症効果等を期待した複数の報告がある(非特許文献6~9)ものの、有効性について一貫した結果を得ていないことが指摘されている(非特許文献10)。
また、化合物1とスタチンとを併用した場合のAAAに対する効果については何ら知られていない。
[1](-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンを組み合わせてなる、大動脈瘤の治療用医薬組成物。
[2]大動脈瘤の治療が、瘤の破裂抑制、瘤の拡大抑制及び瘤の縮小化からなる群から選択される少なくとも一の治療を含む、前記[1]に記載の治療用医薬組成物。
[3]大動脈瘤の治療が大動脈瘤の破裂抑制である、前記[1]又は[2]に記載の治療用医薬組成物。
[4]大動脈瘤の治療が大動脈瘤の拡大抑制である、前記[1]又は[2]に記載の治療用医薬組成物。
[5]ステントグラフト内挿術後の大動脈瘤患者に用いられるものである、前記[1]乃至[4]のいずれか一に記載の治療用医薬組成物。
[6]ステントグラフト内挿術あるいは大動脈瘤切除術(人工血管置換術)前の大動脈瘤患者に用いられるものである、前記[1]乃至[4]のいずれか一に記載の治療用医薬組成物。
[7]大動脈瘤が腹部大動脈瘤である、前記[1]乃至[6]のいずれか一に記載の治療用医薬組成物。
[8]腹部大動脈瘤の最大短径が30mm超、又は40mm超の腹部大動脈瘤患者に用いられるものである、前記[7]に記載の治療用医薬組成物。
[9]腹部大動脈瘤の最大短径が50mm以下の腹部大動脈瘤患者に用いられるものである、前記[8]に記載の治療用医薬組成物。
[10]腹部大動脈瘤の最大短径が50mm超、60mm超、又は70mm超の腹部大動脈瘤患者に用いられるものである、前記[7]又は[8]に記載の治療用医薬組成物。
[11]薬学的に許容される担体を含有するものである、前記[1]乃至[10]のいずれか一に記載の治療用医薬組成物。
[12]スタチンが、プラバスタチン、シンバスタチン、フルバスタチン、アトルバスタチン、ピタバスタチン、及びロスバスタチンからなる群から選択されるスタチンである、前記[1]乃至[11]のいずれか一に記載の治療用医薬組成物。
[13]スタチンが、ピタバスタチン若しくはその塩又はそれらの溶媒和物である、前記[1]乃至[12]のいずれか一に記載の治療用医薬組成物。
[14]スタチンが、ピタバスタチンカルシウム又はピタバスタチンカルシウム水和物である前記[1]乃至[13]のいずれか一に記載の治療用医薬組成物。
[16]必要とされる治療が、大動脈瘤の破裂抑制、拡大抑制及び縮小化からなる群から選択される治療である、前記[15]に記載の治療方法。
[17]必要とされる治療が大動脈瘤の破裂抑制である、前記[15]又は[16]に記載の治療方法。
[18]必要とされる治療が大動脈瘤の拡大抑制である、前記[15]又は[16]に記載の治療方法。
[19]対象がステントグラフト内挿術後の大動脈瘤患者である、前記[15]乃至[18]のいずれか一に記載の治療方法。
[20]対象がステントグラフト内挿術あるいは大動脈瘤切除術(人工血管置換術)前の大動脈瘤患者である、前記[15]乃至[18]のいずれか一に記載の治療方法。
[21]対象が腹部大動脈瘤を有する患者である、前記[15]乃至[20]のいずれか一に記載の治療方法。
[22]対象が最大短径が30mm超、又は40mm超の腹部大動脈瘤を有する患者である、前記[21]に記載の治療方法。
[23]対象が最大短径が50mm以下の腹部大動脈瘤を有する患者である、前記[22]に記載の治療方法。
[24]対象が最大短径が50mm超、60mm超、又は70mm超の腹部大動脈瘤を有する患者である、前記[21]又は[22]に記載の治療方法。
[25]薬学的に許容される担体と共に投与されるものである、前記[15]乃至[24]のいずれか一に記載の治療方法。
[26]スタチンが、プラバスタチン、シンバスタチン、フルバスタチン、アトルバスタチン、ピタバスタチン、及びロスバスタチンからなる群から選択されるスタチンである、前記[15]乃至[25]のいずれか一に記載の治療方法。
[27]スタチンが、ピタバスタチン若しくはその塩又はそれらの溶媒和物である、前記[15]乃至[26]のいずれか一に記載の治療方法。
[28]スタチンが、ピタバスタチンカルシウム又はピタバスタチンカルシウム水和物である、前記[15]乃至[27]のいずれか一に記載の治療方法。
[30]大動脈瘤の治療が、瘤の破裂抑制、瘤の拡大抑制及び瘤の縮小化からなる群から選択される少なくとも一の治療を含む、前記[29]に記載の使用。
[31]大動脈瘤の治療が大動脈瘤の破裂抑制である、前記[29]又は[30]に記載の使用。
[32]大動脈瘤の治療が大動脈瘤の拡大抑制である、前記[29]又は[30]に記載の使用。
[33]ステントグラフト内挿術後の大動脈瘤患者に用いられるものである、前記[29]乃至[32]のいずれか一に記載の使用。
[34]ステントグラフト内挿術あるいは大動脈瘤切除術(人工血管置換術)前の大動脈瘤患者に用いられるものである、前記[29]乃至[32]のいずれか一に記載の使用。
[35]大動脈瘤が腹部大動脈瘤である、前記[29]乃至[34]のいずれか一に記載の使用。
[36]治療用医薬組成物が薬学的に許容される担体を含有するものである、前記[29]乃至[35]のいずれか一に記載の使用。
[37]スタチンが、プラバスタチン、シンバスタチン、フルバスタチン、アトルバスタチン、ピタバスタチン、及びロスバスタチンからなる群から選択されるスタチンである、前記[29]乃至[36]のいずれか一に記載の使用。
[38]スタチンが、ピタバスタチン若しくはその塩又はそれらの溶媒和物である、前記[29]乃至[37]のいずれか一に記載の使用。
[39]スタチンが、ピタバスタチンカルシウム又はピタバスタチンカルシウム水和物である、前記[29]乃至[38]のいずれか一に記載の使用。
[41]大動脈瘤の治療が、瘤の破裂抑制、瘤の拡大抑制及び瘤の縮小化からなる群から選択される少なくとも一の治療を含む、前記[40]に記載の(-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンの組合せ。
[42]大動脈瘤の治療が大動脈瘤の破裂抑制である、前記[40]又は[41]に記載の(-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンの組合せ。
[43]大動脈瘤の治療が大動脈瘤の拡大抑制である、前記[40]又は[41]に記載の(-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンの組合せ。
[44]治療がステントグラフト内挿術後の大動脈瘤患者に対する治療である、前記[40]乃至[43]のいずれか一に記載の(-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンの組合せ。
[45]治療がステントグラフト内挿術あるいは大動脈瘤切除術(人工血管置換術)前の大動脈瘤患者に対する治療である、前記[40]乃至[43]のいずれか一に記載の(-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンの組合せ。
[46]大動脈瘤が腹部大動脈瘤である、前記[40]乃至[45]のいずれか一に記載の(-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンの組合せ。
[47]スタチンが、プラバスタチン、シンバスタチン、フルバスタチン、アトルバスタチン、ピタバスタチン、及びロスバスタチンからなる群から選択されるスタチンである、前記[40]乃至[46]のいずれか一に記載の(-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンの組合せ。
[48]スタチンが、ピタバスタチン若しくはその塩又はそれらの溶媒和物である、前記[40]乃至[47]のいずれか一に記載の(-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンの組合せ。
[49]スタチンが、ピタバスタチンカルシウム又はピタバスタチンカルシウム水和物である、前記[40]乃至[48]のいずれか一に記載の(-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンの組合せ。
[A](-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンを有効成分とする大動脈瘤の治療剤。
[B]大動脈瘤の治療が、瘤の破裂抑制、瘤の拡大抑制及び瘤の縮小化からなる群から選択される少なくとも一の治療を含む、前記[A]に記載の治療剤。
[C](-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンを有効成分とする大動脈瘤の破裂抑制剤。
[D]大動脈瘤が腹部大動脈瘤である、前記[C]に記載の破裂抑制剤。
[E]破裂抑制が、ステントグラフト内挿術後の破裂抑制である、前記[C]又は[D]に記載の破裂抑制剤。
[F](-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンを有効成分とする大動脈瘤の拡大抑制剤。
[G]大動脈瘤が腹部大動脈瘤である、前記[F]に記載の拡大抑制剤。
また、本発明では化合物1の塩若しくは溶媒和物を用いることもできる。化合物1の塩及び溶媒和物は、常法により製造することができる。
プラバスタチン若しくはその塩又はそれらの溶媒和物としては、プラバスタチンナトリウム(化学名:Monosodium(3R,5R)-3,5-dihydroxy-7-{(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8[-(2S)-2-methylbutanoyloxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}heptanoate)が好ましい。
プラバスタチン若しくはその塩又はそれらの溶媒和物は公知の化合物であり、例えば、特開昭57-2240号公報、米国特許第4346227号明細書等に記載の方法により製造することができる。
シンバスタチン若しくはその塩又はそれらの溶媒和物としては、シンバスタチン(化学名:(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate)が好ましい。
シンバスタチン若しくはその塩又はそれらの溶媒和物は公知の化合物であり、例えば、米国特許第4444784号明細書等に記載の方法により製造することができる。
フルバスタチン若しくはその塩又はそれらの溶媒和物としては、フルバスタチンナトリウム(化学名:(±)-(3RS,5SR,6E)-sodium-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoate)が好ましい。
フルバスタチン若しくはその塩又はそれらの溶媒和物は公知の化合物であり、例えば、特表昭60-500015号公報、米国特許第5354772号明細書等に記載の方法により製造することができる。
アトルバスタチン若しくはその塩又はそれらの溶媒和物としては、アトルバスタチンカルシウム水和物(化学名:(-)-Monocalcium bis{(3R,5R)-7-[2-(4-fluorophenyl-5-isopropyl-3-phenyl-4-phenylcarbamoyl-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate]trihydrate})が好ましい。
アトルバスタチン若しくはその塩又はそれらの溶媒和物は公知の化合物であり、例えば、特開平3-58967号公報、米国特許第5273995号明細書等に記載の方法により製造することができる。
ピタバスタチン若しくはその塩又はそれらの溶媒和物としては、ピタバスタチンのカルシウム塩又はその水和物が好ましく、ピタバスタチンカルシウム(化学名:(+)-monocalcium bis{(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate})又はその水和物(特に、5水和物(pentahydrate))が特に好ましい。
ピタバスタチン若しくはその塩又はそれらの溶媒和物は公知の化合物であり、例えば、特開平1-279866号公報、米国特許第5856336号明細書等に記載の方法により製造することができる。
ロスバスタチン若しくはその塩又はそれらの溶媒和物としては、ロスバスタチンカルシウム(化学名:Monocalcium bis ((3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methanesulfonyl(methyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoate))が好ましい。
ロスバスタチン若しくはその塩又はそれらの溶媒和物は公知の化合物であり、例えば、特開平5-178841号公報、米国特許第5260440号明細書等に記載の方法により製造することができる。
当該医薬の具体的態様としては、例えば、大動脈瘤を治療するための医薬品であって、下記の(A)及び(B):
(A)スタチンを含有する大動脈瘤を治療するための医薬;
(B)前記医薬を、化合物1若しくはその塩、又はそれらの溶媒和物と組み合わせて投与することを指示する指示書;
を含む医薬品が挙げられる。当該指示書としては、具体的には例えば、効能・効果や用法・用量などに関する説明事項を記載したいわゆる能書(添付文書)、ラベル(label)などが挙げられる。
当該医薬の具体的態様としては、例えば、大動脈瘤を治療するための医薬品であって、下記の(A)及び(B):
(A)化合物1若しくはその塩、又はそれらの溶媒和物を含有する大動脈瘤を治療するための医薬;
(B)前記医薬を、スタチンと組み合わせて投与することを指示する指示書;
を含む医薬品が挙げられる。当該指示書としては、具体的には例えば、効能・効果や用法・用量などに関する説明事項を記載したいわゆる能書(添付文書)、ラベル(label)などが挙げられる。
医薬の剤形としては、服用の容易性の観点から、経口投与用の固形製剤が好ましく、錠剤、カプセル剤、顆粒剤又は散剤が特に好ましい。
大動脈壁を周囲組織から分離し、カテーテルを挿入した後、腹部大動脈を糸でカテーテルと一緒に結紮する手術によって誘導したラットAAAモデル(非特許文献3)における化合物1及びピタバスタチンの作用を検討した。
なお、本試験において、化合物1は前記特許文献1に記載の方法に従って製造し、一般飼料(FR2,フナバシファーム製)に0.15%混餌し、使用した。また、ピタバスタチンはピタバスタチンカルシウムを一般飼料(FR2,フナバシファーム製)に0.003%混餌し、使用した。
Sprague-Dawley雄性ラット(300-350g:日本SLC)を実験に用いた。室温:25℃±1℃にて飼育し、餌および水は自由に与えた。
非特許文献3記載の方法に従い作成した。すなわち、ラットの大動脈壁を周囲組織から分離し、ポリウレタンカテーテルを挿入した後、腹部大動脈をモノフィラメント糸でプラスチックカテーテルと一緒に結紮し、AAA誘導することによってラットAAAモデルを作成した。
ラットを一般飼料投与群(以下、「対照群」と言う。)(n=22)、化合物1の0.15%混餌飼料投与群(以下、「化合物1群」と言う。)(n=22)と、化合物1の0.15%及びピタバスタチンカルシウムの0.003%混餌飼料投与群(以下、「併用群」と言う。)(n=10)に分けた。一般飼料又は各混餌飼料は、AAAモデル作成手術の1週間前(術前7日)から実験終了まで自由に摂餌させた。
各群とも手術の28日後まで、瘤径をエコーにて測定するとともに、生存を比較した。
また、28日後に生存中の動物を犠牲死させ、AAA病理組織を解析した。
AAA最大短径は手術日、手術後7日、14日、21日及び28日に超音波診断装置(Vevo770,VisualSonics社製)により測定した。
瘤径の測定結果を図1に示す。
対照群、化合物1群に比べて、併用群では、瘤径の拡大が抑制された。特に、術後14日目では対照群に対して、同21日目では対照群及び化合物1群に対して、同28日目では対照群に対して、併用群では瘤径の拡大が有意に抑制された(いずれもp<0.05)。
次に、非破裂生存率の結果を図2に示す。
手術日から手術後28日までの追跡において化合物1群並びに併用群では破裂による死亡率は対照群と比し低く、即ち、生存率の改善傾向を認めた。なお当該期間内に化合物1群では1匹、対照群では2匹、併用群では1匹の原因不明の死亡例が確認され、打ち切りとして以降の生存率、破裂率の集計から除外した。その余の死亡例はいずれもAAAの破裂によるものと剖検で確認された。
以上の結果から、化合物1とスタチンとの併用がAAAの破裂抑制及び拡大抑制において極めて有効であることが明らかとなり、大動脈瘤の治療用医薬組成物、特にはAAAの破裂抑制剤(AAA破裂の予防薬)、AAAの拡大抑制剤(AAA拡大予防薬)として極めて有用であることが明らかとなった。
Claims (7)
- (-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンを有効成分とする大動脈瘤の治療剤。
- 大動脈瘤の治療が、瘤の破裂抑制、瘤の拡大抑制及び瘤の縮小化からなる群から選択される少なくとも一の治療を含む、請求項1に記載の治療剤。
- (-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンを有効成分とする大動脈瘤の破裂抑制剤。
- 大動脈瘤が腹部大動脈瘤である、請求項3に記載の破裂抑制剤。
- 破裂抑制が、ステントグラフト内挿術後の破裂抑制である、請求項3又は4に記載の破裂抑制剤。
- (-)-6-[3-[3-シクロプロピル-3-[(1R,2R)-2-ヒドロキシシクロヘキシル]ウレイド]プロポキシ]-2(1H)-キノリノン若しくはその塩、又はそれらの溶媒和物、及びスタチンを有効成分とする大動脈瘤の拡大抑制剤。
- 大動脈瘤が腹部大動脈瘤である、請求項6に記載の拡大抑制剤。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021505156A JPWO2020184703A1 (ja) | 2019-03-13 | 2020-03-13 | |
EP20770836.3A EP3939656A4 (en) | 2019-03-13 | 2020-03-13 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AORTIC ANEURYSM |
CA3133209A CA3133209A1 (en) | 2019-03-13 | 2020-03-13 | Pharmaceutical composition for treating aortic aneurysm |
MX2021010987A MX2021010987A (es) | 2019-03-13 | 2020-03-13 | Composicion farmaceutica para el tratamiento contra aneurisma aortico. |
BR112021018017A BR112021018017A2 (pt) | 2019-03-13 | 2020-03-13 | Agentes para o tratamento de um aneurisma aórtico e para suprimir a ruptura e a dilatação de aneurisma aórtico |
US17/438,309 US20220184058A1 (en) | 2019-03-13 | 2020-03-13 | Pharmaceutical composition for treating aortic aneurysm |
SG11202109928W SG11202109928WA (en) | 2019-03-13 | 2020-03-13 | Pharmaceutical composition for treating aortic aneurysm |
CN202080009881.7A CN113316469A (zh) | 2019-03-13 | 2020-03-13 | 主动脉瘤的治疗用医药组合物 |
KR1020217019386A KR20210144657A (ko) | 2019-03-13 | 2020-03-13 | 대동맥류의 치료용 의약 조성물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-045333 | 2019-03-13 | ||
JP2019045333 | 2019-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020184703A1 true WO2020184703A1 (ja) | 2020-09-17 |
Family
ID=72427139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/011042 WO2020184703A1 (ja) | 2019-03-13 | 2020-03-13 | 大動脈瘤の治療用医薬組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220184058A1 (ja) |
EP (1) | EP3939656A4 (ja) |
JP (1) | JPWO2020184703A1 (ja) |
KR (1) | KR20210144657A (ja) |
CN (1) | CN113316469A (ja) |
BR (1) | BR112021018017A2 (ja) |
CA (1) | CA3133209A1 (ja) |
MX (1) | MX2021010987A (ja) |
SG (1) | SG11202109928WA (ja) |
TW (1) | TW202100155A (ja) |
WO (1) | WO2020184703A1 (ja) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS572240A (en) | 1980-06-06 | 1982-01-07 | Sankyo Co Ltd | Ml-236b derivative |
US4346227A (en) | 1980-06-06 | 1982-08-24 | Sankyo Company, Limited | ML-236B Derivatives and their preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
JPS60500015A (ja) | 1982-11-22 | 1985-01-10 | サンド・アクチエンゲゼルシヤフト | メバロラクトン同族体とその誘導体、これらの製造法およびこれらを含有する製薬学的組成物 |
JPH01279866A (ja) | 1987-08-20 | 1989-11-10 | Nissan Chem Ind Ltd | キノリン系メバロノラクトン類 |
JPH0358967A (ja) | 1989-07-21 | 1991-03-14 | Warner Lambert Co | 〔R―(R‖,R‖)〕―2―(4―フルオロフエニル)―β,δ―ジヒドロキシ―5―(1―メチルエチル)―3―フエニル―4―〔(フエニルアミノ)カルボニル〕―1H―ピロール―1―ヘプタン酸、そのラクトン体およびその塩 |
JPH05178841A (ja) | 1991-07-01 | 1993-07-20 | Shionogi & Co Ltd | ピリミジン誘導体 |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
WO1997012869A1 (en) | 1995-10-05 | 1997-04-10 | Otsuka Pharmaceutical Company, Limited | Carbostyril derivatives as antithrombotic agents |
WO2006132091A1 (ja) * | 2005-06-08 | 2006-12-14 | Kowa Company, Ltd. | 新規なトリグリセリド低下剤 |
WO2013103148A1 (ja) * | 2012-01-05 | 2013-07-11 | 興和株式会社 | 側副血行路発達促進剤 |
JP2015178460A (ja) * | 2014-03-18 | 2015-10-08 | 国立大学法人浜松医科大学 | 動脈瘤縮小剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007230884A (ja) * | 2006-02-28 | 2007-09-13 | Kowa Co | 脊柱管狭窄症の予防及び/又は治療剤 |
-
2020
- 2020-03-13 CA CA3133209A patent/CA3133209A1/en active Pending
- 2020-03-13 CN CN202080009881.7A patent/CN113316469A/zh active Pending
- 2020-03-13 MX MX2021010987A patent/MX2021010987A/es unknown
- 2020-03-13 WO PCT/JP2020/011042 patent/WO2020184703A1/ja unknown
- 2020-03-13 TW TW109108402A patent/TW202100155A/zh unknown
- 2020-03-13 KR KR1020217019386A patent/KR20210144657A/ko unknown
- 2020-03-13 US US17/438,309 patent/US20220184058A1/en active Pending
- 2020-03-13 EP EP20770836.3A patent/EP3939656A4/en active Pending
- 2020-03-13 JP JP2021505156A patent/JPWO2020184703A1/ja active Pending
- 2020-03-13 SG SG11202109928W patent/SG11202109928WA/en unknown
- 2020-03-13 BR BR112021018017A patent/BR112021018017A2/pt unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS572240A (en) | 1980-06-06 | 1982-01-07 | Sankyo Co Ltd | Ml-236b derivative |
US4346227A (en) | 1980-06-06 | 1982-08-24 | Sankyo Company, Limited | ML-236B Derivatives and their preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
JPS60500015A (ja) | 1982-11-22 | 1985-01-10 | サンド・アクチエンゲゼルシヤフト | メバロラクトン同族体とその誘導体、これらの製造法およびこれらを含有する製薬学的組成物 |
JPH01279866A (ja) | 1987-08-20 | 1989-11-10 | Nissan Chem Ind Ltd | キノリン系メバロノラクトン類 |
US5856336A (en) | 1987-08-20 | 1999-01-05 | Nissan Chemical Industries Ltd. | Quinoline type mevalonolactones |
JPH0358967A (ja) | 1989-07-21 | 1991-03-14 | Warner Lambert Co | 〔R―(R‖,R‖)〕―2―(4―フルオロフエニル)―β,δ―ジヒドロキシ―5―(1―メチルエチル)―3―フエニル―4―〔(フエニルアミノ)カルボニル〕―1H―ピロール―1―ヘプタン酸、そのラクトン体およびその塩 |
US5273995A (en) | 1989-07-21 | 1993-12-28 | Warner-Lambert Company | [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof |
JPH05178841A (ja) | 1991-07-01 | 1993-07-20 | Shionogi & Co Ltd | ピリミジン誘導体 |
US5260440A (en) | 1991-07-01 | 1993-11-09 | Shionogi Seiyaku Kabushiki Kaisha | Pyrimidine derivatives |
WO1997012869A1 (en) | 1995-10-05 | 1997-04-10 | Otsuka Pharmaceutical Company, Limited | Carbostyril derivatives as antithrombotic agents |
WO2006132091A1 (ja) * | 2005-06-08 | 2006-12-14 | Kowa Company, Ltd. | 新規なトリグリセリド低下剤 |
WO2013103148A1 (ja) * | 2012-01-05 | 2013-07-11 | 興和株式会社 | 側副血行路発達促進剤 |
JP2015178460A (ja) * | 2014-03-18 | 2015-10-08 | 国立大学法人浜松医科大学 | 動脈瘤縮小剤 |
Non-Patent Citations (17)
Title |
---|
"The Japanese Pharmacopoeia", article "General Rules for Preparations" |
ANN. SURG., vol. 241, no. 1, 2005, pages 92 - 101 |
ARTERIOSCLER. THROMB. VASE. BIOL., vol. 37, no. 3, March 2017 (2017-03-01), pages 401 - 10 |
ATHEROSCLEROSIS, vol. 202, no. 1, 2009, pages 34 - 40 |
ATHEROSCLEROSIS, vol. 210, no. 1, 2010, pages 51 - 6 |
BIOCHEM. BIOPHYS. RESEARCH COMMUN., vol. 353, no. 4, 2007, pages 1111 - 14 |
EUR. J. VASE. ENDOVASC. SURG., vol. 50, no. 6, 2015, pages 702 - 13 |
INT. J. MOL. SCI., vol. 16, no. 5, 2015, pages 11213 - 28 |
J. VASE. SURG., vol. 43, no. 1, 2006, pages 117 - 24 |
KAJIMOTO, KAN: "Positioning and subject of statin in arteriosclerotic diseases-4 abdominal aortic aneurysm/peripheral artery disease, column of peripheral artery disease and statin", JOURNAL OF PRACTICAL PHARMACY, vol. 67, no. 9, 2016, pages 54 - 58, XP009531093 * |
KOGA, Y. ET AL.: "2 (1H) -Quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, 1998, pages 1471 - 1476, XP004137066, DOI: 10.1016/S0960-894X(98)00246-7 * |
PLOS ONE, vol. 10, no. 8, 2015, pages e0134386 |
SCI. REP., vol. 6, 2016, pages 31268 |
See also references of EP3939656A4 |
TAKAGI, H. ET AL.: "A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion", J. VASC. SURG., vol. 52, no. 5, 2010, pages 1675 - 1681, XP027560544 * |
UMEBAYASHI, R. ET AL.: "Cilostazol attenuated angiotensin II-induced abdominal aortic aneurysms in apolipoprotein E deficient mice", PROGRAMS AND PROCEEDINGS OF THE 44TH JAPAN ATHEROSCLEROSIS SOCIETY, 2012, pages 252, XP009519906 * |
ZHANG, Q. ET AL.: "Suppression of experimental abdominal aortic aneurysm in a rat model by the phosphodiesterase 3 inhibitor cilostazo l", J OURNAL OF SURGICAL RESEARCH, vol. 167, 2011, pages e385 - e393, XP028190003, DOI: 10.1016/j.jss.2011.01.017 * |
Also Published As
Publication number | Publication date |
---|---|
MX2021010987A (es) | 2021-12-15 |
US20220184058A1 (en) | 2022-06-16 |
JPWO2020184703A1 (ja) | 2020-09-17 |
CN113316469A (zh) | 2021-08-27 |
EP3939656A1 (en) | 2022-01-19 |
TW202100155A (zh) | 2021-01-01 |
EP3939656A4 (en) | 2022-12-07 |
KR20210144657A (ko) | 2021-11-30 |
BR112021018017A2 (pt) | 2021-11-23 |
SG11202109928WA (en) | 2021-10-28 |
CA3133209A1 (en) | 2020-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005538104A (ja) | コレステロール吸収阻害剤、HMG−CoAレダクターゼ阻害剤および安定化剤を含有する組成物 | |
JP4839309B2 (ja) | 血栓症治療剤 | |
CN1642574B (zh) | 用于肾小球疾病的治疗剂 | |
KR101258422B1 (ko) | 신규의 트리글리세리드 저하제 | |
WO2020184703A1 (ja) | 大動脈瘤の治療用医薬組成物 | |
ES2622893T3 (es) | Tratamiento de la pared arterial mediante la combinación de un inhibidor del SRAA y un inhibidor de la HMG-CoA reductasa | |
JP2008522955A (ja) | リピド・リッチ・プラークの縮小、安定化及び破裂予防方法 | |
JPWO2006011495A1 (ja) | 高コレステロール血症及び/又は高トリグリセリド血症治療剤 | |
JP7300387B2 (ja) | 大動脈瘤の治療用医薬組成物 | |
JP2007513991A (ja) | メタボリック症候群の処置のためのスタチンの使用 | |
WO2019216313A1 (ja) | 心血管疾患に有用な医薬 | |
WO2008015763A1 (fr) | Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire | |
JPWO2005117853A1 (ja) | 高脂血症治療剤及び糖尿病治療剤 | |
JP2003535875A (ja) | 新規製剤 | |
JP2013526499A (ja) | キサンチンオキシダーゼ阻害剤およびスタチンの合剤およびその使用 | |
JP2003104894A (ja) | 動脈瘤治療剤または予防剤 | |
JPWO2006095704A1 (ja) | 肝癌の治療方法 | |
KR20100109840A (ko) | 분비성 포스포리파제 a2 (spla2) 억제제를 사용한 심혈관 질환 및 이상지혈증의 치료 및 spla2 억제제 조합 요법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20770836 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021505156 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3133209 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021018017 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020770836 Country of ref document: EP Effective date: 20211013 |
|
ENP | Entry into the national phase |
Ref document number: 112021018017 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210910 |